Intracellular Valuation
| ITCI Stock | USD 85.69 0.24 0.28% |
At this time, the firm appears to be overvalued. Intracellular Th retains a regular Real Value of $80.79 per share. The prevalent price of the firm is $85.69. Our model calculates the value of Intracellular Th from evaluating the firm fundamentals such as Return On Asset of -0.0745, current valuation of 8.1 B, and Return On Equity of -0.099 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Intracellular's valuation include:
Price Book 7.9354 | Enterprise Value 8.1 B | Enterprise Value Ebitda (37.12) | Price Sales 14.8023 | Forward PE 217.3913 |
Overvalued
Today
Please note that Intracellular's price fluctuation is very steady at this time. Calculation of the real value of Intracellular Th is based on 3 months time horizon. Increasing Intracellular's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Intracellular is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Intracellular Stock. However, Intracellular's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 85.69 | Real 80.79 | Target 77.83 | Hype 86.55 | Naive 79.89 |
The intrinsic value of Intracellular's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Intracellular's stock price.
Estimating the potential upside or downside of Intracellular Th helps investors to forecast how Intracellular stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Intracellular more accurately as focusing exclusively on Intracellular's fundamentals will not take into account other important factors: When choosing an evaluation method for Intracellular Th, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Intracellular Cash |
|
Intracellular Valuation Trend
Intracellular's real value analysis enables investors to forecast the earnings more efficiently. Using both Intracellular's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Intracellular Revenue by Product
Intracellular Total Value Analysis
Intracellular Th is currently forecasted to have valuation of 8.1 B with market capitalization of 9.08 B, debt of 16.94 M, and cash on hands of 628.74 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Intracellular fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.1 B | 9.08 B | 16.94 M | 628.74 M |
Intracellular Investor Information
About 96.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.87. Intracellular Th had not issued any dividends in recent years. Based on the analysis of Intracellular's profitability, liquidity, and operating efficiency, Intracellular Th is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Intracellular Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Intracellular has an asset utilization ratio of 63.76 percent. This signifies that the Company is making $0.64 for each dollar of assets. An increasing asset utilization means that Intracellular Th is more efficient with each dollar of assets it utilizes for everyday operations.Intracellular Ownership Allocation
Intracellular Th has a total of 106.02 Million outstanding shares. The majority of Intracellular Th outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intracellular to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intracellular Th. Please pay attention to any change in the institutional holdings of Intracellular Th as this could imply that something significant has changed or is about to change at the company. On July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Intracellular Th's common stock.Intracellular Profitability Analysis
The company reported the previous year's revenue of 464.37 M. Net Loss for the year was (139.67 M) with profit before overhead, payroll, taxes, and interest of 95.16 M.About Intracellular Valuation
An absolute valuation paradigm, as applied to Intracellular Stock, attempts to find the value of Intracellular Th based on its fundamental and basic technical indicators. By analyzing Intracellular's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Intracellular's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Intracellular. We calculate exposure to Intracellular's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Intracellular's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 430.6 M | 452.2 M | |
| Pretax Profit Margin | (0.30) | (0.31) | |
| Operating Profit Margin | (0.34) | (0.36) | |
| Net Loss | (0.30) | (0.32) | |
| Gross Profit Margin | 0.93 | 0.97 |
Intracellular Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 95.9 M | |
| Forward Price Earnings | 217.3913 |
Intracellular Current Valuation Indicators
Valuation refers to the process of determining the present value of Intracellular Th and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Intracellular we look at many different elements of the entity such as Intracellular's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Intracellular, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Intracellular's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Intracellular's worth.Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |